Literature DB >> 9237721

Variance of plasma human immunodeficiency virus type 1 RNA levels measured by branched DNA within and between days.

S G Deeks1, R L Coleman, R White, C Pachl, M Schambelan, D N Chernoff, M B Feinberg.   

Abstract

Previous studies have shown that CD4-positive T cells vary in a predictable manner over 24 h. This diurnal variance has significant clinical implications. Recently, viral RNA measurements have been increasingly used as a standard marker in the management of human immunodeficiency virus (HIV)-infected patients. Little detailed analysis of the variability of this marker has been conducted. To define the variance of plasma HIV-1 RNA levels within days, 11 clinically stable patients with established HIV infection and a baseline viral RNA level >40,000 copies/mL were studied. Following the patients' admission to an inpatient research unit, plasma samples were obtained frequently over 48 h and analyzed for HIV-1 RNA levels by use of a quantitative branched chain DNA assay (bDNA). No diurnal pattern was detected. In these clinically stable patients, viral RNA levels exhibited a variance of approximately 0.4 log.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9237721     DOI: 10.1086/517278

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

1.  Comparative evaluation of two branched-DNA human immunodeficiency virus type 1 RNA quantification assays with lower detection limits of 50 and 500 copies per milliliter.

Authors:  C Manegold; C Krempe; H Jablonowski; L Kajala; M Dietrich; O Adams
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  Longitudinal variability of human immunodeficiency virus type 1 RNA viral load measurements by nucleic acid sequence-based amplification and NucliSens assays in a large multicenter study.

Authors:  M J Nowicki; L Benning; J W Bremer; W A Meyer; C Hanson; D Brambilla; S Silver; A Kovacs
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

3.  Reproducibility and performance of the second-generation branched-DNA assay in routine quantification of human immunodeficiency virus type 1 RNA in plasma.

Authors:  D G Murphy; P Gonin; M Fauvel
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

Review 4.  Modeling antiretroviral drug responses for HIV-1 infected patients using differential equation models.

Authors:  Yanni Xiao; Hongyu Miao; Sanyi Tang; Hulin Wu
Journal:  Adv Drug Deliv Rev       Date:  2013-04-17       Impact factor: 15.470

5.  Variation in cell-associated unspliced HIV RNA on antiretroviral therapy is associated with the circadian regulator brain-and-muscle-ARNT-like-1.

Authors:  Christina C Chang; Vivek Naranbhai; Jared Stern; Michael Roche; Ashanti Dantanarayana; Ruian Ke; Surekha Tennakoon; Ajantha Solomon; Rebecca Hoh; Wendy Hartogensis; Frederick M Hecht; Ken Sikaris; David J Price; Julian H Elliott; Steven G Deeks; Melissa Churchill; Paul U Cameron; Nicolas Hengartner; Alan S Perelson; Sharon R Lewin
Journal:  AIDS       Date:  2018-09-24       Impact factor: 4.177

6.  Viral Load Monitoring in HIV Infection.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-12       Impact factor: 3.663

7.  Clinical prognostic value of RNA viral load and CD4 cell counts during untreated HIV-1 infection--a quantitative review.

Authors:  Eline L Korenromp; Brian G Williams; George P Schmid; Christopher Dye
Journal:  PLoS One       Date:  2009-06-17       Impact factor: 3.240

8.  Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite Pathogenicity.

Authors:  Frederic Bertels; Alex Marzel; Gabriel Leventhal; Venelin Mitov; Jacques Fellay; Huldrych F Günthard; Jürg Böni; Sabine Yerly; Thomas Klimkait; Vincent Aubert; Manuel Battegay; Andri Rauch; Matthias Cavassini; Alexandra Calmy; Enos Bernasconi; Patrick Schmid; Alexandra U Scherrer; Viktor Müller; Sebastian Bonhoeffer; Roger Kouyos; Roland R Regoes
Journal:  Mol Biol Evol       Date:  2018-01-01       Impact factor: 16.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.